Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAK HFpEF Trial
NCT05138575Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jan 2022
- Primary completion
- May 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin, potassium nitrate in heart failure with preserved ejection fraction (HFpEF), sponsored by University of Pennsylvania. Started Jan 2022; status: recruiting.
02
Drugs
empagliflozinpotassium nitrate
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05138575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138575.